Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
复制标题
DOI：
10.1186/s13550-015-0114-2
复制
发表时间：
2015-12
期刊：
影响因子：
3.2
通讯作者：
Essler M
中科院分区：
文献类型：
--
作者：
Ahmadzadehfar H;Rahbar K;Kürpig S;Bögemann M;Claesener M;Eppard E;Gärtner F;Rogenhofer S;Schäfers M;Essler M
使用 177Lu-DKFZ-617 PSMA (Lu-PSMA)（前列腺特异性膜抗原）进行放射配体治疗 (RLT) 是一种治疗转移性前列腺癌的新型靶向疗法。我们回顾性分析了在我们科室接受 Lu-PSMA 治疗的第一批患者的早期副作用和缓解率。对 10 名患有远处转移和疾病进展的激素和/或化疗难治性患者（平均年龄 73.5 岁）进行了 RLT。所有患者在 RLT 之前均进行了 68Ga-PSMA HBED-CC PET/CT。治疗前的中位 PSA 水平为 298.5 ng/ml（范围 5-853 ng/ml）。所有患者在用药前一天和用药后 2 天接受全血细胞计数 (CBC)、肾功能和肝功能检查（平均给药活性 5.6 GBq，范围 4.1-6.1 GBq），随后每 2 周进行进一步检查。每周通过电话联系所有患者，了解副作用或任何积极和消极的变化。治疗八周后，7 名患者 (70%) 出现 PSA 下降，其中 6 名患者下降超过 30%，5 名患者下降超过 50%。根据 PSA 的增加，三名患者表现出疾病进展。注射 Lu-PSMA 后，没有患者立即出现任何副作用。仅一名患者在给药 7 周后出现相关血液毒性（3 级或 4 级）。同一患者表现出 2 级白细胞减少症。两名患者仅表现出 1 种血液细胞系紊乱，而一名患者表现出白细胞和血小板分别为 1 级和 2 级减少。六名患者在治疗后 8 周内没有表现出任何血液毒性。没有相关的肾毒性（3 级或 4 级）。我们的初步结果表明，使用 Lu-PSMA 进行 RLT 是安全的，并且早期副作用似乎较低。 70% 的患者检测到相关 PSA 下降。
Radioligand therapy (RLT) with 177Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PSMA in our departments. RLT was performed in ten hormone- and/or chemo-refractory patients with distant metastases and progressive disease (mean age 73.5 years). 68Ga-PSMA HBED-CC PET/CT was performed in all patients prior to RLT. The median PSA level prior to the therapy was 298.5 ng/ml (range 5–853 ng/ml). All patients received CBC, renal and liver function tests the day before and 2 days after application (mean administered activity 5.6 GBq, range 4.1–6.1 GBq), followed by further tests every 2 weeks. All patients were contacted by telephone every week regarding side effects or any positive and negative changes. Eight weeks after the therapy, seven patients (70 %) experienced a PSA decline, of whom six experienced more than 30 % and five more than 50 %. Three patients showed a progressive disease according to the PSA increase. No patient experienced any side effects immediately after injection of Lu-PSMA. Relevant hematotoxicity (grade 3 or 4) occurred 7 weeks after the administration in just one patient. The same patient showed a leucopenia grade 2. Two patients showed a disturbance of only 1 hematologic cell line, whereas one patient showed a reduction of grades 1 and 2 in leucocytes and thrombocytes, respectively. Six patients did not show any hematotoxicity during the 8 weeks after therapy. There was no relevant nephrotoxicity (grade 3 or 4). Our initial results indicate that RLT with Lu-PSMA is safe and seems to have low early side-effect profile. A relevant PSA decline was detected in 70 % of patients.
登录
查看更多内容
影响因子：
45.3
作者：
Milowsky, MI;Nanus, DM;Bander, NH
通讯作者：
Bander, NH
影响因子：
51.1
作者：
Ryan, Charles J.;Smith, Matthew R.;Rathkopf, Dana E.
通讯作者：
Rathkopf, Dana E.
影响因子：
158.5
作者：
Scher, Howard I.;Fizazi, Karim;de Bono, Johann S.
通讯作者：
de Bono, Johann S.
影响因子：
4.8
作者：
Wei, Q.;Li, M.;Li, Y.
通讯作者：
Li, Y.
DOI：
10.1007/s00259-014-2713-y
发表时间：
2014-07
影响因子：
9.1
作者：
Zechmann, Christian M.;Afshar-Oromieh, Ali;Armor, Tom;Stubbs, James B.;Mier, Walter;Hadaschik, Boris;Joyal, John;Kopka, Klaus;Debus, Juergen;Babich, John W.;Haberkorn, Uwe
通讯作者：
Haberkorn, Uwe